title: The effect of insulin therapy on biomechanical deterioration of bone in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats.
abstract: OBJECTIVE
  To investigate the effect of insulin therapy on biomechanical properties of bone in streptozotocin (STZ)-induced type 1 diabetes mellitus (T1DM) in rats.
  
  
  METHODS
  A total of 28 male Wistar-Albino rats (12-week-old; 210-300g) were divided into 4 groups (n=7 for each) including control [C; no treatment], sham [Sh; distilled water i.p., for 8 weeks], diabetes [T1DM; 65mg/kg of STZ, single i.p.] and diabetes+insulin treatment [T1DM+I; 65mg/kg of STZ, single i.p.+insulin; 2-4UI/day/rat, i.p., for 8 weeks] groups. Body weight, blood glucose levels (BGLs), bone mineral density (BMD) and geometric/mechanical properties of bone tissue were evaluated.
  
  
  RESULTS
  BGLs in diabetic rats were significantly increased compared to non-diabetic rats, while the body weights were decreased (p<0.05). Femur length and cross-sectional area of femur were significantly decreased in both T1DM and T1DM+I groups (p<0.05). The significant reduction obtained in BMD in T1DM rats compared with C and Sh (p<0.05) groups was reversed by insulin treatment (p<0.05). Displacement, absorbed energy, maximum load, ultimate stress and toughness were significantly decreased inT1DM and T1DM+I groups compared to C and Sh groups (p<0.05).
  
  
  CONCLUSIONS
  In conclusion, insulin treatment seems to be ineffective in restoration of biomechanical deterioration of bone specific to STZ-induced T1DM.
authors.affiliation: Department of Biophysics, Mersin University, Faculty of Medicine, TR-33169 Mersin, Turkey. nerdal@mersin.edu.tr
authors.forename: Nurten
authors.initials: N
authors.lastname: Erdal
authors.forename: Serkan
authors.initials: S
authors.lastname: Gürgül
authors.forename: Can
authors.initials: C
authors.lastname: Demirel
authors.forename: Altan
authors.initials: A
authors.lastname: Yildiz
mesh_terms: D000818:Animals; D001696:Biomechanical Phenomena / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001847:Bone Diseases / Q000209:etiology* / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy*; D005269:Femur / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D013311:Streptozocin